首页 > 最新文献

Acta Gastro-Enterologica Belgica最新文献

英文 中文
A pilot randomized trial to study the success rate of early precut fistulotomy and its effect on radiation dose in patients with difficult biliary cannulation 研究胆道插管困难患者早期预切瘘成功率及其对放射剂量的影响
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2021-11-01 DOI: 10.51821/84.4.005
H. Mandavdhare, J. Shah, R. Kakadiya, P. Kumar M, P. Gupta, H. Singh, V. Sharma, U. Dutta
Background: Role of precut fistulotomy in reducing fluoroscopy time and the radiation dose in difficult selective biliary cannulation is unknown.Methods: We performed a randomized trial where patients with difficult biliary cannulation were randomized into 2 groups: early precut fistulotomy (precut five minutes after failed standard biliary cannulation) or late precut fistulotomy (precut fifteen minutes after failed standard biliary cannulation). We compared the success rates of selective biliary cannulation, fluoroscopy time, radiation dose, complication rates, need for repeat endoscopic retrograde cholangiography (ERC) and need for other interventionsResults: Of the 130 eligible patients screened, 40 patients were randomized. The technical success was comparable between early and late group. The fluoroscopy time and radiation dose were significantly less in the early group [4 minutes (3, 6) vs 15 minutes (8, 28), p=0.001] and [1.35 mGy (0.90, 1.63) vs 2.40 mGy (1.58, 3.25), p=0.010] respectively. In the late group, 60% required need for rescue precut fistulotomy. One patient from late group developed post ERC pancreatitis while 1 from early group developed perforation. Three needed other interventions due to failed second attempt.Conclusion: Early precut fistulotomy has comparable technical success and reduces the radiation dose as compared to late precut fistulotomy for difficult biliary cannulation.
背景:在困难的选择性胆道插管中,切开前瘘管切开术在减少透视时间和放射剂量方面的作用尚不清楚。方法:采用随机试验方法,将胆道插管困难患者随机分为2组:早期预切瘘管(标准胆道插管失败后5分钟预切)和晚期预切瘘管(标准胆道插管失败后15分钟预切)。我们比较了选择性胆道插管的成功率、透视时间、放射剂量、并发症发生率、需要重复内镜逆行胆道造影(ERC)和需要其他干预措施。结果:在筛选的130例符合条件的患者中,随机选择了40例患者。技术上的成功在早组和晚组之间是相当的。早期组的透视时间和放射剂量均明显少于[4分钟(3,6)vs 15分钟(8,28),p=0.001]和[1.35 mGy (0.90, 1.63) vs 2.40 mGy (1.58, 3.25), p=0.010]。晚期组中,60%需要行抢救性预切瘘术。晚期组1例发生ERC后胰腺炎,早期组1例发生穿孔。由于第二次尝试失败,其中3人需要其他干预。结论:在胆道插管困难的情况下,早期预切瘘管与晚期预切瘘管相比,在技术上取得了相当的成功,并减少了放射剂量。
{"title":"A pilot randomized trial to study the success rate of early precut fistulotomy and its effect on radiation dose in patients with difficult biliary cannulation","authors":"H. Mandavdhare, J. Shah, R. Kakadiya, P. Kumar M, P. Gupta, H. Singh, V. Sharma, U. Dutta","doi":"10.51821/84.4.005","DOIUrl":"https://doi.org/10.51821/84.4.005","url":null,"abstract":"Background: Role of precut fistulotomy in reducing fluoroscopy time and the radiation dose in difficult selective biliary cannulation is unknown.\u0000\u0000Methods: We performed a randomized trial where patients with difficult biliary cannulation were randomized into 2 groups: early precut fistulotomy (precut five minutes after failed standard biliary cannulation) or late precut fistulotomy (precut fifteen minutes after failed standard biliary cannulation). We compared the success rates of selective biliary cannulation, fluoroscopy time, radiation dose, complication rates, need for repeat endoscopic retrograde cholangiography (ERC) and need for other interventions\u0000\u0000Results: Of the 130 eligible patients screened, 40 patients were randomized. The technical success was comparable between early and late group. The fluoroscopy time and radiation dose were significantly less in the early group [4 minutes (3, 6) vs 15 minutes (8, 28), p=0.001] and [1.35 mGy (0.90, 1.63) vs 2.40 mGy (1.58, 3.25), p=0.010] respectively. In the late group, 60% required need for rescue precut fistulotomy. One patient from late group developed post ERC pancreatitis while 1 from early group developed perforation. Three needed other interventions due to failed second attempt.\u0000\u0000Conclusion: Early precut fistulotomy has comparable technical success and reduces the radiation dose as compared to late precut fistulotomy for difficult biliary cannulation.","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"43 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82270311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute pancreatitis and obesity: where is the problem? 急性胰腺炎和肥胖:问题在哪里?
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
E Mahfouz, N Lanthier
{"title":"Acute pancreatitis and obesity: where is the problem?","authors":"E Mahfouz, N Lanthier","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"104"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37070697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic hepatitis C testing of people in treatment for substance use disorders in Belgium between 2011 and 2014 : a cross-sectional study. 2011年至2014年比利时药物使用障碍治疗中丙型肝炎诊断检测:一项横断面研究。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
L Van Baelen, J Antoine, K De Ridder, G Muyldermans, L Gremeaux

Background: Hepatitis C prevalence figures for people who use drugs in Belgium are scarce, and particularly for people who inject drugs. The current study refines the existing HCV estimates by focussing on diagnostic HCV testing practices for this population at risk.

Methods: The analysis is the result of a descriptive crosssectional study, based on data extracted from the linkage between a database of people in treatment for substance use disorders in Belgium and a database of the Belgian health insurance companies. By using national nomenclature codes for HCV tests, the number of people in treatment for substance use disorders who were tested on HCV, were estimated.

Results: 18,880 out of 30,905 patients (61.1%) in treatment for substance use disorders between 2011 and 2014 have been screened at least once for HCV between 2008 and 2015. 58.0% of those who had never injected and 59.1% of those with an unknown injecting status were tested for HCV, compared to 86.5% of the patients who had recently injected and 84.5% of those who had ever injected. 36.8% of the people who had recently injected were tested for HCV RNA.

Conclusions: This study supports the need of a continued effort of health care providers to identify people infected with HCV. For a population at risk such as people who use drugs, regular screening is needed to reach the goal set by WHO of near viral elimination of HCV by 2030.

背景:在比利时,丙型肝炎流行率的数据很少,特别是注射毒品的人。目前的研究通过关注这一高危人群的丙型肝炎病毒诊断检测实践,改进了现有的丙型肝炎病毒估计。方法:分析是描述性横断面研究的结果,基于从比利时物质使用障碍治疗人群数据库和比利时健康保险公司数据库之间的联系中提取的数据。通过使用丙型肝炎病毒检测的国家命名代码,估计了接受丙型肝炎病毒检测的药物使用障碍患者的人数。结果:在2011年至2014年期间接受药物使用障碍治疗的30905名患者中,有18880名(61.1%)在2008年至2015年期间至少接受过一次HCV筛查。58.0%从未注射过的患者和59.1%注射状态不明的患者接受了HCV检测,而最近注射过的患者和曾经注射过的患者的这一比例分别为86.5%和84.5%。36.8%最近注射的人进行了HCV RNA检测。结论:本研究支持卫生保健提供者继续努力识别丙型肝炎病毒感染者的必要性。对于吸毒者等高危人群,需要定期进行筛查,以实现世卫组织制定的到2030年几乎消除丙型肝炎病毒的目标。
{"title":"Diagnostic hepatitis C testing of people in treatment for substance use disorders in Belgium between 2011 and 2014 : a cross-sectional study.","authors":"L Van Baelen,&nbsp;J Antoine,&nbsp;K De Ridder,&nbsp;G Muyldermans,&nbsp;L Gremeaux","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis C prevalence figures for people who use drugs in Belgium are scarce, and particularly for people who inject drugs. The current study refines the existing HCV estimates by focussing on diagnostic HCV testing practices for this population at risk.</p><p><strong>Methods: </strong>The analysis is the result of a descriptive crosssectional study, based on data extracted from the linkage between a database of people in treatment for substance use disorders in Belgium and a database of the Belgian health insurance companies. By using national nomenclature codes for HCV tests, the number of people in treatment for substance use disorders who were tested on HCV, were estimated.</p><p><strong>Results: </strong>18,880 out of 30,905 patients (61.1%) in treatment for substance use disorders between 2011 and 2014 have been screened at least once for HCV between 2008 and 2015. 58.0% of those who had never injected and 59.1% of those with an unknown injecting status were tested for HCV, compared to 86.5% of the patients who had recently injected and 84.5% of those who had ever injected. 36.8% of the people who had recently injected were tested for HCV RNA.</p><p><strong>Conclusions: </strong>This study supports the need of a continued effort of health care providers to identify people infected with HCV. For a population at risk such as people who use drugs, regular screening is needed to reach the goal set by WHO of near viral elimination of HCV by 2030.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"35-42"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37069926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The future of Acta Gastro-Enterologica Belgica. 《比利时胃肠病学学报》的未来。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
N Lanthier, T G Moreels
{"title":"The future of Acta Gastro-Enterologica Belgica.","authors":"N Lanthier,&nbsp;T G Moreels","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"3-4"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37070908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The history of Acta Gastro-Enterologica Belgica. 《比利时胃肠病学学报》的历史。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
T G Moreels, R Fiasse, N Lanthier

The history of Acta Gastro-Enterologica Belgica is long, rich… and cloudy. There is no centralised archive available. However, all currently active gastroenterologists in Belgium have been trained with the journal, have published abstracts or manuscripts in it, or at least know of its existence. Whereas it started as a national society's journal in 1933, it has grown to a competitive international journal with Impact Factor. We felt the need to reconstruct the journal's long history, since this was never done before. This review tried to highlight some of the important milestones, without claiming to be complete. Looking back helps to better foresee and anticipate the future.

《比利时胃肠病学学报》的历史源远流长,内容丰富……没有可用的集中存档。然而,比利时目前所有活跃的胃肠病学家都接受过该杂志的培训,在其中发表过摘要或手稿,或者至少知道它的存在。从1933年开始,它是一个国家学会的期刊,它已经发展成为具有影响力因子的具有竞争力的国际期刊。我们觉得有必要重建这份杂志的悠久历史,因为这是以前从未做过的。这篇综述试图突出一些重要的里程碑,但并不声称已经完成。回顾过去有助于更好地预见和预测未来。
{"title":"The history of Acta Gastro-Enterologica Belgica.","authors":"T G Moreels,&nbsp;R Fiasse,&nbsp;N Lanthier","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The history of Acta Gastro-Enterologica Belgica is long, rich… and cloudy. There is no centralised archive available. However, all currently active gastroenterologists in Belgium have been trained with the journal, have published abstracts or manuscripts in it, or at least know of its existence. Whereas it started as a national society's journal in 1933, it has grown to a competitive international journal with Impact Factor. We felt the need to reconstruct the journal's long history, since this was never done before. This review tried to highlight some of the important milestones, without claiming to be complete. Looking back helps to better foresee and anticipate the future.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"57-61"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37069929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multicentre, observational study on demographic and disease characteristics of patients seeking care for chronic hepatitis C in Belgium in 2016. 2016年比利时慢性丙型肝炎患者人口统计学和疾病特征多中心观察性研究
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
S Bourgeois, J P Mulkay, L Lasser, G Robaeys, B Bastens, J Delwaide, S Pollet, M Van den Enden

Background and study aims: Direct-acting antivirals provide interferon-free treatments for chronic hepatitis C (CHC) virus infection. In Belgium, in 2016, access to these agents was limited to patients with advanced liver fibrosis stages F3 and F4. This study is the first to describe Belgium's patient population ineligible for interferon-free treatment.

Patients and methods: This was an observational, cross-sectional, multicentre study that enrolled adult patients with CHC ineligible for interferon-free treatment. Patient data recorded at a single visit included demographic data, disease characteristics, comorbidities, co-medications, treatment status, and laboratory data.

Results: Three hundred and three patients from 16 centres in Belgium were included in the statistical analysis. On average, patients were aged 53.5 years and 50.2% were women ; 94.1% had health insurance and 99.0% resided in Belgium. The current hepatitis C virus (HCV) infection was the first infection for 96.0% of patients and the mean time since infection was 20.0 years. Liver fibrosis stage was F0 for 23.7%, F0/F1 or F1 for 38.3%, F1/F2 or F2 for 25.8%, F3 for 7.1%, and F4 for 5.1% of patients ; 28.4% of patients were CHC treatment-experienced. The main reason for ineligibility for interferon-free treatment was lack of reimbursement (84.8%). Other reasons included no treatment urgency or medical decision to wait (27.1%), waiting for future treatment option (8.3%), and no social insurance coverage (3.6%).

Conclusions: This study provides recent data on the CHC patient population and disease characteristics in Belgium that could help medical communities and government agencies manage CHC disease burden.

背景与研究目的:直接作用抗病毒药物为慢性丙型肝炎(CHC)病毒感染提供无干扰素治疗。2016年,在比利时,这些药物仅限F3和F4期晚期肝纤维化患者使用。这项研究首次描述了比利时不符合无干扰素治疗条件的患者群体。患者和方法:这是一项观察性、横断面、多中心研究,纳入了不适合无干扰素治疗的成年CHC患者。单次就诊记录的患者数据包括人口统计数据、疾病特征、合并症、联合用药、治疗状况和实验室数据。结果:来自比利时16个中心的303例患者被纳入统计分析。患者平均年龄53.5岁,女性50.2%;94.1%的人有健康保险,99.0%的人居住在比利时。96.0%的患者首次感染丙型肝炎病毒(HCV),平均感染时间为20.0年。肝纤维化分期为F0的占23.7%,F0/F1或F1的占38.3%,F1/F2或F2的占25.8%,F3的占7.1%,F4的占5.1%;28.4%的患者经历过CHC治疗。无干扰素治疗不合格的主要原因是缺乏报销(84.8%)。其他原因包括没有治疗紧急或医疗决定等待(27.1%),等待未来的治疗方案(8.3%),以及没有社会保险覆盖(3.6%)。结论:本研究提供了比利时CHC患者人群和疾病特征的最新数据,可以帮助医疗界和政府机构管理CHC疾病负担。
{"title":"A multicentre, observational study on demographic and disease characteristics of patients seeking care for chronic hepatitis C in Belgium in 2016.","authors":"S Bourgeois,&nbsp;J P Mulkay,&nbsp;L Lasser,&nbsp;G Robaeys,&nbsp;B Bastens,&nbsp;J Delwaide,&nbsp;S Pollet,&nbsp;M Van den Enden","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background and study aims: </strong>Direct-acting antivirals provide interferon-free treatments for chronic hepatitis C (CHC) virus infection. In Belgium, in 2016, access to these agents was limited to patients with advanced liver fibrosis stages F3 and F4. This study is the first to describe Belgium's patient population ineligible for interferon-free treatment.</p><p><strong>Patients and methods: </strong>This was an observational, cross-sectional, multicentre study that enrolled adult patients with CHC ineligible for interferon-free treatment. Patient data recorded at a single visit included demographic data, disease characteristics, comorbidities, co-medications, treatment status, and laboratory data.</p><p><strong>Results: </strong>Three hundred and three patients from 16 centres in Belgium were included in the statistical analysis. On average, patients were aged 53.5 years and 50.2% were women ; 94.1% had health insurance and 99.0% resided in Belgium. The current hepatitis C virus (HCV) infection was the first infection for 96.0% of patients and the mean time since infection was 20.0 years. Liver fibrosis stage was F0 for 23.7%, F0/F1 or F1 for 38.3%, F1/F2 or F2 for 25.8%, F3 for 7.1%, and F4 for 5.1% of patients ; 28.4% of patients were CHC treatment-experienced. The main reason for ineligibility for interferon-free treatment was lack of reimbursement (84.8%). Other reasons included no treatment urgency or medical decision to wait (27.1%), waiting for future treatment option (8.3%), and no social insurance coverage (3.6%).</p><p><strong>Conclusions: </strong>This study provides recent data on the CHC patient population and disease characteristics in Belgium that could help medical communities and government agencies manage CHC disease burden.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"43-52"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37069931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Whipple's disease in a man of North African descent : case report and brief review of the literature. 一名北非裔男子的惠普尔病:病例报告及文献综述。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
M Lenfant, J Callemeyn, H Alaerts, W Meersseman, W Van Moerkercke

A 62-year-old man of North African descent presented with weight loss in the past year and diarrhea for three weeks. His medical history included erosive rheumatoid arthritis, treated with methotrexate and adalimumab. Histological examination of a duodenal biopsy showed foamy macrophages in the lamina propria, with PAS-positive cytoplasmatic inclusions. These findings are compatible with Whipple's disease, a rare chronic infectious disease caused by Tropheryma whipplei, an opportunistic bacterium. It is typically seen in middle-aged Caucasian men and the immunocompromised host. The classical presentation of Whipple's disease consists of intermittent migratory arthralgia, followed by intestinal symptoms which typically occur six to seven years later. The clinical image can be very variable, and this complicates the diagnostic process. PAS-staining and PCR are the diagnostic cornerstones. In our case, treatment consisted of a prolonged cure of antibiotics: intravenous ceftriaxone for two weeks, followed by an oral maintenance therapy of doxycycline and hydroxychloroquine for at least one year. A therapeutic dilemma arose as continued anti-TNF blockade was necessary to maintain remission of the rheumatoid arthritis. Lifelong follow-up is necessary because relapse is possible.

一名62岁的北非裔男子在过去一年中出现体重下降和腹泻三周。病史包括糜烂性类风湿关节炎,曾用甲氨蝶呤和阿达木单抗治疗。十二指肠活检组织学检查显示固有层有泡沫状巨噬细胞,伴有pas阳性的胞浆包涵体。这些发现与惠普尔病相一致,惠普尔病是一种罕见的慢性传染病,由一种机会性细菌惠普尔Tropheryma whipplei引起。它通常见于中年高加索男性和免疫功能低下的宿主。惠普尔氏病的典型表现包括间歇性迁移性关节痛,随后通常在6至7年后出现肠道症状。临床图像可能非常多变,这使诊断过程复杂化。pas染色和PCR是诊断的基础。在我们的病例中,治疗包括延长抗生素治疗:静脉注射头孢曲松两周,然后口服强力霉素和羟氯喹维持治疗至少一年。由于持续的抗tnf阻断是维持类风湿关节炎缓解所必需的,因此出现了治疗困境。终身随访是必要的,因为复发是可能的。
{"title":"Whipple's disease in a man of North African descent : case report and brief review of the literature.","authors":"M Lenfant,&nbsp;J Callemeyn,&nbsp;H Alaerts,&nbsp;W Meersseman,&nbsp;W Van Moerkercke","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 62-year-old man of North African descent presented with weight loss in the past year and diarrhea for three weeks. His medical history included erosive rheumatoid arthritis, treated with methotrexate and adalimumab. Histological examination of a duodenal biopsy showed foamy macrophages in the lamina propria, with PAS-positive cytoplasmatic inclusions. These findings are compatible with Whipple's disease, a rare chronic infectious disease caused by Tropheryma whipplei, an opportunistic bacterium. It is typically seen in middle-aged Caucasian men and the immunocompromised host. The classical presentation of Whipple's disease consists of intermittent migratory arthralgia, followed by intestinal symptoms which typically occur six to seven years later. The clinical image can be very variable, and this complicates the diagnostic process. PAS-staining and PCR are the diagnostic cornerstones. In our case, treatment consisted of a prolonged cure of antibiotics: intravenous ceftriaxone for two weeks, followed by an oral maintenance therapy of doxycycline and hydroxychloroquine for at least one year. A therapeutic dilemma arose as continued anti-TNF blockade was necessary to maintain remission of the rheumatoid arthritis. Lifelong follow-up is necessary because relapse is possible.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"83-86"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37071266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Toothpick a day, keeps the doctor away? 一天一根牙签,医生远离我?
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
L Depoorter, T Billiet, M Verhamme, W Van Moerkercke

A Toothpick is a dreaded offender when ingested, as it is risky to cause impaction, obstruction or perforation of the gut. When ingestion of a toothpick leads to one of these complications, it clinically mimics an acute abdomen. Often the patient doesn't recall the ingestion, leading to misdiagnosis as inflammatory bowel disease, appendicitis/diverticulitis, etc. We describe the case of a 50-year old woman presenting to the emergency department with right lower abdominal pain. CT-scan showed an obstruction without clear underlying cause. The hypothesis of obstruction due to intestinal adhesions without strangulation was assumed and non-operative management lead to recovery and dismissal of the patient. However, she presented 3 weeks later with identical complaints, this time showing a terminal ileitis on CT-scan. Surprisingly, a toothpick perforating the terminal ileum was found during endoscopy and could by removed. A clinician should think of foreign body ingestion when patients present with an acute abdomen with no clear underlying pathology.

牙签是一个可怕的罪犯,当被摄入时,因为它有可能导致肠道嵌塞、阻塞或穿孔。当摄入牙签导致其中一种并发症时,它在临床上模拟了急腹症。患者经常不记得摄入,导致误诊为炎症性肠病、阑尾炎/憩室炎等。我们描述的情况下,一个50岁的妇女呈现到急诊科右下腹部疼痛。ct扫描显示梗阻没有明确的根本原因。假设肠梗阻是由于肠道粘连而非绞窄,非手术治疗导致患者康复并出院。然而,3周后,她再次出现相同的症状,这次在ct扫描上显示为终末期回肠炎。令人惊讶的是,在内窥镜检查中发现一根牙签穿过回肠末端,可以被移除。当患者出现急腹症而没有明确的基础病理时,临床医生应考虑异物摄入。
{"title":"A Toothpick a day, keeps the doctor away?","authors":"L Depoorter,&nbsp;T Billiet,&nbsp;M Verhamme,&nbsp;W Van Moerkercke","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A Toothpick is a dreaded offender when ingested, as it is risky to cause impaction, obstruction or perforation of the gut. When ingestion of a toothpick leads to one of these complications, it clinically mimics an acute abdomen. Often the patient doesn't recall the ingestion, leading to misdiagnosis as inflammatory bowel disease, appendicitis/diverticulitis, etc. We describe the case of a 50-year old woman presenting to the emergency department with right lower abdominal pain. CT-scan showed an obstruction without clear underlying cause. The hypothesis of obstruction due to intestinal adhesions without strangulation was assumed and non-operative management lead to recovery and dismissal of the patient. However, she presented 3 weeks later with identical complaints, this time showing a terminal ileitis on CT-scan. Surprisingly, a toothpick perforating the terminal ileum was found during endoscopy and could by removed. A clinician should think of foreign body ingestion when patients present with an acute abdomen with no clear underlying pathology.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"97-98"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37071269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Terminal ileitis after kidney transplantation : Crohn's disease or other? Case reports and literature review. 肾移植后终末期回肠炎:克罗恩病还是其他?病例报告及文献回顾。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
E Motté, L Pipeleers, K Wilgenhof, H Reynaert, D Urbain, F Mana

The finding of a terminal ileitis after kidney transplantation can cause a diagnostic challenge. Because the development of Crohn's disease under immunosuppressive therapy is unlikely, this diagnosis should only be considered after exclusion of infectious disease and drug-related intestinal toxicity. Defining the underlying cause of terminal ileitis is often hampered by a shortage of specific diagnostic tests or their lack of sensitivity. We present three patients with terminal ileitis after kidney transplantation resulting from different etiologies. Subsequently, we describe the characteristics that can help to make the differential diagnosis.

肾移植后发现终末期回肠炎可引起诊断挑战。由于在免疫抑制治疗下克罗恩病不太可能发展,因此只有在排除感染性疾病和药物相关肠道毒性后才能考虑这种诊断。确定终末期回肠炎的根本原因往往受到缺乏特定诊断测试或缺乏敏感性的阻碍。我们报告了三例肾移植后因不同病因导致的终末期回肠炎。随后,我们描述的特点,可以帮助作出鉴别诊断。
{"title":"Terminal ileitis after kidney transplantation : Crohn's disease or other? Case reports and literature review.","authors":"E Motté,&nbsp;L Pipeleers,&nbsp;K Wilgenhof,&nbsp;H Reynaert,&nbsp;D Urbain,&nbsp;F Mana","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The finding of a terminal ileitis after kidney transplantation can cause a diagnostic challenge. Because the development of Crohn's disease under immunosuppressive therapy is unlikely, this diagnosis should only be considered after exclusion of infectious disease and drug-related intestinal toxicity. Defining the underlying cause of terminal ileitis is often hampered by a shortage of specific diagnostic tests or their lack of sensitivity. We present three patients with terminal ileitis after kidney transplantation resulting from different etiologies. Subsequently, we describe the characteristics that can help to make the differential diagnosis.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"63-66"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37069930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rectal cancer surgery : what's in a name? 直肠癌手术:名字有什么关系?
IF 1.5 4区 医学 Q2 Medicine Pub Date : 2019-01-01
N Komen, P Dewint, S Van den Broeck, S Pauli, H de Schepper

The field of rectal cancer treatment is a dynamic and changing field, due to better understanding of the pathology and new medical treatment options, but perhaps mostly due to innovations in the surgical approach. Surgery is the cornerstone for rectal cancer treatment. Currently, Total Mesorectal Excision is the gold standard. After evolution towards laparoscopic TME, improving technology has led to the development of platforms that allow transanal TME and robotic TME. In addition, local excision can be performed safer and more accurately by means of Transanal Endoscopic Microsurgery (TEM), TransAnal Minimally Invasive Surgery or Endoscopic Submucosal Dissection (ESD), possibly avoiding TME. The aim of this review is to summarize the different surgical techniques and approaches for rectal cancer in function of tumor stage and describe the specifics of the technique.

直肠癌治疗领域是一个动态和不断变化的领域,由于对病理学的更好理解和新的医学治疗选择,但可能主要是由于手术方法的创新。手术是直肠癌治疗的基石。目前,全肠系膜切除术是金标准。在向腹腔镜TME发展之后,技术的改进导致了经肛门TME和机器人TME平台的发展。此外,经肛门内镜显微手术(TEM)、经肛门微创手术(ESD)或内镜粘膜下剥离术(ESD)可以更安全、更准确地进行局部切除,可能避免TME。本综述的目的是总结不同的手术技术和入路的直肠癌在肿瘤分期的功能和描述技术的特点。
{"title":"Rectal cancer surgery : what's in a name?","authors":"N Komen,&nbsp;P Dewint,&nbsp;S Van den Broeck,&nbsp;S Pauli,&nbsp;H de Schepper","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The field of rectal cancer treatment is a dynamic and changing field, due to better understanding of the pathology and new medical treatment options, but perhaps mostly due to innovations in the surgical approach. Surgery is the cornerstone for rectal cancer treatment. Currently, Total Mesorectal Excision is the gold standard. After evolution towards laparoscopic TME, improving technology has led to the development of platforms that allow transanal TME and robotic TME. In addition, local excision can be performed safer and more accurately by means of Transanal Endoscopic Microsurgery (TEM), TransAnal Minimally Invasive Surgery or Endoscopic Submucosal Dissection (ESD), possibly avoiding TME. The aim of this review is to summarize the different surgical techniques and approaches for rectal cancer in function of tumor stage and describe the specifics of the technique.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"82 1","pages":"67-74"},"PeriodicalIF":1.5,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37069932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Gastro-Enterologica Belgica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1